Skip to main content
TipRanks
Go Ultimate75% OFF

Nexalin Technology, Inc. (NXL) Risk Analysis

281 Followers
Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F). Risk factors show the challenges a company faces. Investors can consider the worst-case scenarios before making an investment. TipRanks’ Risk Analysis categorizes risks based on proprietary classification algorithms and machine learning. Nexalin Technology, Inc. disclosed 56 risk factors in its most recent earnings report. Nexalin Technology, Inc. reported the most risks in the “Finance & Corporate” category.

Risk Overview Q3, 2026

Source: the company's latest filing for the period ended Sep 30, 2026, filed Nov 12, 2026

Risk Distribution
56Risks
Sector Avg.Finance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Risk Change Over Time

Nexalin Technology, Inc. disclosed risks per quarterNo. of Risks455055606570Q4Q12023Q2Q4Q3Q4Q2Q3Q4Q12026Q3Showing: Q3, 2026
Risks removedRisks addedRisks changedNexalin Technology, Inc. Risk Factors
  • Share Price & Shareholder Rights - Risk 1
    Our continued listing on Nasdaq is subject to compliance with the minimum stockholders' equity requirement, and a delisting could materially and adversely affect the trading market for and value of our common stock.

    On January 21, 2026, the Company received a deficiency letter from the Listing Qualifications Department of Nasdaq notifying the Company that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. The Company was provided an initial 180-calendar-day compliance period, which expired on July 20, 2026, to regain compliance with the minimum bid price requirement. The Company did not regain compliance during the initial compliance period. On July 24, 2026, Nasdaq notified us that we were not eligible for an automatic additional 180-calendar-day compliance period because we did not satisfy the minimum stockholders' equity requirement applicable to an initial listing on the Nasdaq Capital Market. Nasdaq issued a Staff Delisting Determination advising us that, unless we timely requested a hearing before a Nasdaq Hearings Panel, trading in our common stock would be suspended and Nasdaq would commence delisting proceedings. The Company timely requested a hearing before the Panel, which stayed the suspension and delisting of our common stock pending the Panel's decision. On August 28, 2026, the Company effected a one-for-thirty reverse stock split of its issued and outstanding common stock as part of its efforts to regain compliance with the minimum bid price requirement. The Company appeared before the Panel on September 1, 2026. On September 25, 2026, the Company received written notification from the Panel granting our request for continued listing, subject to demonstrating compliance with the minimum bid price requirement on or before September 28, 2026, and the minimum stockholders' equity requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1) on or before January 4, 2027. On September 30, 2026, Nasdaq formally confirmed that the Company had regained compliance with the minimum bid price requirement. Our common stock remains listed on the Nasdaq Capital Market; however, our continued listing remains subject to demonstrating compliance with the minimum stockholders' equity requirement by January 4, 2027. Our ability to regain compliance depends, in part, on our operating results and our ability to raise additional capital. There can be no assurance that we will satisfy that requirement within the period granted by the Panel or maintain compliance with the minimum bid price requirement or Nasdaq's other continued-listing standards. If we fail to satisfy the Panel's conditions or otherwise fail to meet Nasdaq's continued-listing requirements, our common stock could be delisted. If Nasdaq delists our common stock from trading on its exchange and we are not able to list our common stock on another national securities exchange, we expect our common stock could be quoted on an over-the-counter market. If this were to occur, we could face significant adverse consequences, including: - a limited availability of market quotations for our common stock;- reduced liquidity for our common stock;- the possibility that our common stock is a "penny stock," which would require brokers trading in our common stock to adhere to more stringent rules and could result in a reduced level of trading activity in the secondary trading market for our securities;- a limited amount of news and analyst coverage; and - a decreased ability to obtain additional financing in the future.

  • Share Price & Shareholder Rights - Risk 2
    A delisting of our common stock or other limitations could impair our ability to raise capital under our at-the-market offering program and Any Market Purchase Agreement.

    We have historically funded our operations primarily through equity and debt financings, including sales of common stock under our at-the-market offering program (the "ATM Program"). We have also entered into an Any Market Purchase Agreement (the "AMPA"), pursuant to which we may, subject to specified conditions and limitations, direct the investor to purchase shares of our common stock from time to time. Our ability to use the ATM Program depends on the availability and continued effectiveness of the applicable registration statement and our satisfaction of the eligibility requirements for conducting primary offerings on Form S-3. Our ability to sell shares under the AMPA is also subject to numerous conditions, including the effectiveness of an applicable resale registration statement, compliance with Nasdaq requirements, applicable beneficial-ownership and exchange-cap limitations, the market price and trading volume of our common stock, and the continued trading of our common stock on an eligible principal market. If our common stock is delisted from Nasdaq, we may lose or experience a material impairment of our ability to sell shares under the ATM Program and the AMPA. Even if our common stock remains listed, declines in its market price or trading volume, limitations imposed by Nasdaq rules or securities laws, or the failure to satisfy other applicable conditions could substantially reduce the amount of capital available under these arrangements. The stated capacities of the ATM Program and the AMPA do not represent cash on hand or assurance that funding will be available when needed, and there can be no assurance that we will be able to raise any particular amount under either arrangement. We have generated limited operating revenue, have experienced recurring operating losses and negative operating cash flows, and have substantial doubt about our ability to continue as a going concern. If we cannot raise sufficient capital through the ATM Program, the AMPA or other financing sources, we may be required to delay, reduce or eliminate planned clinical, regulatory, product-development or commercialization activities, including our pivotal insomnia clinical trial, or pursue other strategic alternatives. Alternative financing may not be available when needed or may be available only on terms that are highly dilutive or otherwise unfavorable to us and our stockholders.

  • Share Price & Shareholder Rights - Risk 3
    The effects of our one-for-thirty reverse stock split may not be sustained, and the reverse stock split may adversely affect the market price and liquidity of our common stock.

    On August 28, 2026, we effected a one-for-thirty reverse stock split of our issued and outstanding common stock as part of our efforts to regain compliance with Nasdaq's minimum bid price requirement. On September 30, 2026, Nasdaq formally confirmed that we had regained compliance with that requirement. However, there can be no assurance that the increase in our per-share trading price following the reverse stock split will be sustained or that we will maintain compliance with the minimum bid price requirement. Our continued listing also remains subject to demonstrating compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million on or before January 4, 2027, and maintaining compliance with Nasdaq's other continued-listing requirements. The market price of our common stock may decline following the reverse stock split, and any increase in the per-share market price may be proportionally less than the reduction in the number of outstanding shares. Consequently, the aggregate market value of our common stock could decline. The reverse stock split may also reduce the liquidity of our common stock, increase price volatility, increase the number of stockholders holding fewer than 100 shares, commonly referred to as "odd lots," and increase transaction costs for those stockholders. The reduced number of outstanding shares may further concentrate ownership and make it more difficult for investors to purchase or sell significant quantities of our common stock without affecting its market price. The reverse stock split proportionately adjusted the number of shares issuable under our equity compensation plans and upon the exercise of outstanding stock options and warrants, as well as the applicable exercise prices. It also resulted in adjustments to the remaining consideration shares and applicable pricing provisions under the PONM Stock Purchase Agreement. These adjustments do not eliminate the potential dilution resulting from the future exercise of outstanding equity awards or warrants or the issuance of the remaining PONM consideration shares. At our 2026 Annual Meeting of Stockholders, our stockholders authorized our Board of Directors, in its discretion, to effect one or more reverse stock splits at ratios ranging from one-for-two to one-for-one hundred, provided that the cumulative effect of all reverse stock splits implemented under that authorization may not exceed one-for-two hundred fifty. The one-for-thirty reverse stock split used only a portion of that authorization. If our Board determines to implement an additional reverse stock split, it could further reduce the number of outstanding shares, trading liquidity and the number of shares held by individual stockholders. An additional reverse stock split also may not result in a sustained increase in the market price of our common stock or enable us to maintain compliance with Nasdaq's continued-listing requirements.

  • Share Price & Shareholder Rights - Risk 4
    Sales of common stock under our financing arrangements, the exercise of outstanding warrants and resales by selling stockholders may result in substantial dilution and could adversely affect the market price of our common stock.

    We have issued, and may continue to issue, a substantial number of shares of our common stock in connection with financing transactions. During the third quarter of 2026, we issued 80,645 shares of common stock in a registered direct offering and warrants to purchase an additional 40,323 shares of common stock at an exercise price of $15.00 per share. We also entered into the AMPA, under which we may, subject to specified conditions and limitations, sell shares of common stock having an aggregate purchase price of up to $15,000,000. In October 2026, we issued 100,732 shares of common stock to Alumni Capital LP in satisfaction of the $300,000 commitment fee under the AMPA. These commitment shares were issued as common stock rather than pre-funded warrants and did not generate cash proceeds for the Company. The resale registration statement covering up to 5,752,822 shares of common stock was declared effective on October 15, 2026. The registered shares include shares issuable under the AMPA, commitment shares and shares underlying the warrants issued in connection with the registered direct offering. Registration does not necessarily mean that all such shares will be issued or sold. However, the issuance or resale of a substantial number of shares, or the perception that such issuances or resales may occur, could adversely affect the market price of our common stock and make it more difficult for us to sell equity securities in the future at prices that we consider acceptable. The purchase price for shares sold under the AMPA is based on a discount to market prices determined over specified measurement periods. Accordingly, if the market price of our common stock declines, we may be required to issue a greater number of shares to raise the same amount of proceeds, resulting in greater dilution to existing stockholders. Sales under the AMPA may also place downward pressure on the market price of our common stock, which could further increase the number of shares required to be issued in subsequent sales. Our ability to issue shares under the AMPA remains subject to Nasdaq stockholder-approval requirements, applicable exchange-cap and beneficial-ownership limitations, the continued effectiveness and availability of the resale registration statement and other contractual conditions. Subsequent to September 30, 2026, we sold an additional 219,593 shares of common stock under the ATM Program. We may issue additional shares under the ATM Program, equity compensation plans, acquisition agreements or other financing and strategic arrangements. These issuances may substantially dilute the ownership and voting interests of our existing stockholders. The outstanding warrants issued in the registered direct offering may be exercised only at the election of their holders. We will not receive additional proceeds unless those warrants are exercised for cash, and they may expire without being exercised. If the warrants are exercised, the issuance of the underlying shares will result in additional dilution. The actual dilution resulting from these arrangements will depend on the number of shares issued, the applicable issuance prices, the market price of our common stock and the extent to which outstanding warrants are exercised. Significant dilution or a substantial increase in the number of shares available for public resale could adversely affect the market price and trading liquidity of our common stock.

  • Debt & Financing - Risk 5
    Our outstanding debt obligations could adversely affect our liquidity, limit our financial flexibility and impair our ability to fund our operations.

    On August 21, 2026, we issued an unsecured promissory note with an original principal amount of $1.17 million, which matures on February 21, 2027. The note requires us to make mandatory prepayments equal to 20% of the proceeds received from certain equity and other financing transactions, subject to the terms of the note. These mandatory prepayments reduce the amount of financing proceeds available to fund our operations, including our ongoing clinical trials, research and development activities, regulatory initiatives and general corporate expenses. We have incurred significant operating losses and negative cash flows from operations and will require additional capital to fund our business. Our ability to repay the note at maturity or upon an earlier required payment will depend on our available cash resources, our ability to obtain additional financing and other factors, many of which are outside our control. If we are unable to satisfy our obligations under the note, we could be subject to an event of default and related remedies available to the lender under the terms of the note, which could further adversely affect our liquidity and financial condition. In addition, the requirement to use a portion of future financing proceeds to repay outstanding debt may limit our ability to deploy capital toward our clinical development programs and other strategic initiatives. Any inability to satisfy our debt obligations, or the need to obtain additional financing on unfavorable terms to meet those obligations, could materially adversely affect our business, financial condition, results of operations and ability to continue as a going concern.

  • Corporate Activity and Growth - Risk 6
    We completed the acquisition of PONM, Inc. during the second quarter of 2026, and we may not realize the anticipated benefits of that acquisition or the related licensed technology.

    On May 14, 2026, we acquired all of the outstanding equity interests of PONM, Inc. from GreenLight Ventures, LLC ("GLV") for aggregate consideration of approximately $1.3 million payable in shares of our common stock. Substantially all of the value acquired relates to certain software and associated intellectual-property rights licensed within specified fields of use. As of September 30, 2026, the related finite-lived intangible asset had a carrying amount of approximately $648,000 and is being amortized on a straight-line basis over an estimated useful life of seven years. The licensed software, standing alone, does not include all features, functionality, integrations or enhancements that may be necessary to operate our business or commercialize our devices at scale. Additional development, customization, testing and integration will be required, which we expect to obtain in whole or in part from GLV under a Collaboration Agreement. The completion of that work may take longer or cost more than anticipated, may not result in commercially viable capabilities, and may divert management and financial resources from other activities. If the acquired technology does not perform as expected, cannot be successfully integrated with our devices and clinical workflows, or does not achieve market acceptance, we may not realize the anticipated benefits of the acquisition. We could also be required to recognize an impairment charge against the carrying amount of the acquired intangible asset, which could materially adversely affect our results of operations. We depend on GLV for the continued development, maintenance and support of the acquired technology, and our relationship with GLV constitutes a related-party arrangement. Dr. David Owens, a member of our Board of Directors and our Chief Medical Officer, holds a minority ownership interest in GLV. The Collaboration Agreement has an initial term of 24 months, and we cannot assure you that GLV will satisfactorily perform its obligations, that the agreement will be renewed or extended on acceptable terms, or that we could replace GLV's services on a timely or cost-effective basis. Our rights to the licensed software are limited to specified fields of use, and GLV retains rights outside those fields. These limitations may restrict our ability to expand the Nexalin NeuroCare™ platform into additional applications or prevent us from restricting GLV or other licensees from developing technologies that may compete with certain platform capabilities. The license could also be terminated, narrowed, challenged or otherwise become unavailable to us, which could impair our ability to develop or commercialize the platform. As of September 30, 2026, consideration valued at approximately $209,400 remained payable in two additional tranches of our common stock scheduled for issuance 180 and 270 days after the acquisition date. On November 10, 2026, we issued 87,301 shares of common stock in settlement of the third tranche. The number and value of shares ultimately issued are subject to contractual pricing provisions, including applicable floors, ceilings and adjustments for specified issuances and capital events. The remaining consideration may also accelerate upon certain events, including a change of control. The issuance of the remaining consideration shares will dilute our existing stockholders. The amount of dilution could be significant if the market price of our common stock declines or if provisions of the acquisition agreements require us to issue a greater number of shares than currently estimated. Changes in the estimated value of the deferred share consideration may also increase the carrying amount of the acquired intangible asset and our future amortization expense.

Read and Evaluate the RiskReserved for Ultimate MembersUpgrade

Risk Highlights Q3, 2026

Main Risk Category
Finance & Corporate
With 23 Risks
Number of Disclosed Risks
56
+5
From last report
S&P 500 Average: 32
Recent Changes
6Risks added
0Risks removed
0Risks changed
Since Sep 2026
Number of Risk Changed
0
No changes from last report
S&P 500 Average: 1

Risk Word Cloud

our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.to assess our future viabilitywe expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.expect to expand our developmentif we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.confidentiality of our trade secretswe may be subject to anti-monopoly concerns as a result of our doing business in china.subject to anti-monopoly concernsthe u.s. fda, chinese national medical products administration and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.chinese national medical products administrationwe do not intend to pay cash dividends on our common stock in the foreseeable future.intend to pay cash dividendswe rely on third parties to conduct clinical trials for our products, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with applicable regulatory requirements.including failing to meet deadlinesthere may be difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in china against us based on foreign laws.effecting service of legal processwe will require additional funding to meet our financial needs and to pursue our business objectives. if we are unable to raise capital when needed, we could be forced to delay, reduce or altogether cease our product development programs or commercialization efforts.to pursue our business objectiveswe are subject to the risks of conducting business internationally.risks of conducting business internationally

Risk Factors Full Breakdown - Total Risks 56

Share Price & Shareholder Rights12 | 21.4%
  • Share Price & Shareholder Rights - Risk 1Added
    Our continued listing on Nasdaq is subject to compliance with the minimum stockholders' equity requirement, and a delisting could materially and adversely affect the trading market for and value of our common stock.

    On January 21, 2026, the Company received a deficiency letter from the Listing Qualifications Department of Nasdaq notifying the Company that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. The Company was provided an initial 180-calendar-day compliance period, which expired on July 20, 2026, to regain compliance with the minimum bid price requirement. The Company did not regain compliance during the initial compliance period. On July 24, 2026, Nasdaq notified us that we were not eligible for an automatic additional 180-calendar-day compliance period because we did not satisfy the minimum stockholders' equity requirement applicable to an initial listing on the Nasdaq Capital Market. Nasdaq issued a Staff Delisting Determination advising us that, unless we timely requested a hearing before a Nasdaq Hearings Panel, trading in our common stock would be suspended and Nasdaq would commence delisting proceedings. The Company timely requested a hearing before the Panel, which stayed the suspension and delisting of our common stock pending the Panel's decision. On August 28, 2026, the Company effected a one-for-thirty reverse stock split of its issued and outstanding common stock as part of its efforts to regain compliance with the minimum bid price requirement. The Company appeared before the Panel on September 1, 2026. On September 25, 2026, the Company received written notification from the Panel granting our request for continued listing, subject to demonstrating compliance with the minimum bid price requirement on or before September 28, 2026, and the minimum stockholders' equity requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1) on or before January 4, 2027. On September 30, 2026, Nasdaq formally confirmed that the Company had regained compliance with the minimum bid price requirement. Our common stock remains listed on the Nasdaq Capital Market; however, our continued listing remains subject to demonstrating compliance with the minimum stockholders' equity requirement by January 4, 2027. Our ability to regain compliance depends, in part, on our operating results and our ability to raise additional capital. There can be no assurance that we will satisfy that requirement within the period granted by the Panel or maintain compliance with the minimum bid price requirement or Nasdaq's other continued-listing standards. If we fail to satisfy the Panel's conditions or otherwise fail to meet Nasdaq's continued-listing requirements, our common stock could be delisted. If Nasdaq delists our common stock from trading on its exchange and we are not able to list our common stock on another national securities exchange, we expect our common stock could be quoted on an over-the-counter market. If this were to occur, we could face significant adverse consequences, including: - a limited availability of market quotations for our common stock;- reduced liquidity for our common stock;- the possibility that our common stock is a "penny stock," which would require brokers trading in our common stock to adhere to more stringent rules and could result in a reduced level of trading activity in the secondary trading market for our securities;- a limited amount of news and analyst coverage; and - a decreased ability to obtain additional financing in the future.

  • Share Price & Shareholder Rights - Risk 2Added
    A delisting of our common stock or other limitations could impair our ability to raise capital under our at-the-market offering program and Any Market Purchase Agreement.

    We have historically funded our operations primarily through equity and debt financings, including sales of common stock under our at-the-market offering program (the "ATM Program"). We have also entered into an Any Market Purchase Agreement (the "AMPA"), pursuant to which we may, subject to specified conditions and limitations, direct the investor to purchase shares of our common stock from time to time. Our ability to use the ATM Program depends on the availability and continued effectiveness of the applicable registration statement and our satisfaction of the eligibility requirements for conducting primary offerings on Form S-3. Our ability to sell shares under the AMPA is also subject to numerous conditions, including the effectiveness of an applicable resale registration statement, compliance with Nasdaq requirements, applicable beneficial-ownership and exchange-cap limitations, the market price and trading volume of our common stock, and the continued trading of our common stock on an eligible principal market. If our common stock is delisted from Nasdaq, we may lose or experience a material impairment of our ability to sell shares under the ATM Program and the AMPA. Even if our common stock remains listed, declines in its market price or trading volume, limitations imposed by Nasdaq rules or securities laws, or the failure to satisfy other applicable conditions could substantially reduce the amount of capital available under these arrangements. The stated capacities of the ATM Program and the AMPA do not represent cash on hand or assurance that funding will be available when needed, and there can be no assurance that we will be able to raise any particular amount under either arrangement. We have generated limited operating revenue, have experienced recurring operating losses and negative operating cash flows, and have substantial doubt about our ability to continue as a going concern. If we cannot raise sufficient capital through the ATM Program, the AMPA or other financing sources, we may be required to delay, reduce or eliminate planned clinical, regulatory, product-development or commercialization activities, including our pivotal insomnia clinical trial, or pursue other strategic alternatives. Alternative financing may not be available when needed or may be available only on terms that are highly dilutive or otherwise unfavorable to us and our stockholders.

  • Share Price & Shareholder Rights - Risk 3Added
    The effects of our one-for-thirty reverse stock split may not be sustained, and the reverse stock split may adversely affect the market price and liquidity of our common stock.

    On August 28, 2026, we effected a one-for-thirty reverse stock split of our issued and outstanding common stock as part of our efforts to regain compliance with Nasdaq's minimum bid price requirement. On September 30, 2026, Nasdaq formally confirmed that we had regained compliance with that requirement. However, there can be no assurance that the increase in our per-share trading price following the reverse stock split will be sustained or that we will maintain compliance with the minimum bid price requirement. Our continued listing also remains subject to demonstrating compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million on or before January 4, 2027, and maintaining compliance with Nasdaq's other continued-listing requirements. The market price of our common stock may decline following the reverse stock split, and any increase in the per-share market price may be proportionally less than the reduction in the number of outstanding shares. Consequently, the aggregate market value of our common stock could decline. The reverse stock split may also reduce the liquidity of our common stock, increase price volatility, increase the number of stockholders holding fewer than 100 shares, commonly referred to as "odd lots," and increase transaction costs for those stockholders. The reduced number of outstanding shares may further concentrate ownership and make it more difficult for investors to purchase or sell significant quantities of our common stock without affecting its market price. The reverse stock split proportionately adjusted the number of shares issuable under our equity compensation plans and upon the exercise of outstanding stock options and warrants, as well as the applicable exercise prices. It also resulted in adjustments to the remaining consideration shares and applicable pricing provisions under the PONM Stock Purchase Agreement. These adjustments do not eliminate the potential dilution resulting from the future exercise of outstanding equity awards or warrants or the issuance of the remaining PONM consideration shares. At our 2026 Annual Meeting of Stockholders, our stockholders authorized our Board of Directors, in its discretion, to effect one or more reverse stock splits at ratios ranging from one-for-two to one-for-one hundred, provided that the cumulative effect of all reverse stock splits implemented under that authorization may not exceed one-for-two hundred fifty. The one-for-thirty reverse stock split used only a portion of that authorization. If our Board determines to implement an additional reverse stock split, it could further reduce the number of outstanding shares, trading liquidity and the number of shares held by individual stockholders. An additional reverse stock split also may not result in a sustained increase in the market price of our common stock or enable us to maintain compliance with Nasdaq's continued-listing requirements.

  • Share Price & Shareholder Rights - Risk 4Added
    Sales of common stock under our financing arrangements, the exercise of outstanding warrants and resales by selling stockholders may result in substantial dilution and could adversely affect the market price of our common stock.

    We have issued, and may continue to issue, a substantial number of shares of our common stock in connection with financing transactions. During the third quarter of 2026, we issued 80,645 shares of common stock in a registered direct offering and warrants to purchase an additional 40,323 shares of common stock at an exercise price of $15.00 per share. We also entered into the AMPA, under which we may, subject to specified conditions and limitations, sell shares of common stock having an aggregate purchase price of up to $15,000,000. In October 2026, we issued 100,732 shares of common stock to Alumni Capital LP in satisfaction of the $300,000 commitment fee under the AMPA. These commitment shares were issued as common stock rather than pre-funded warrants and did not generate cash proceeds for the Company. The resale registration statement covering up to 5,752,822 shares of common stock was declared effective on October 15, 2026. The registered shares include shares issuable under the AMPA, commitment shares and shares underlying the warrants issued in connection with the registered direct offering. Registration does not necessarily mean that all such shares will be issued or sold. However, the issuance or resale of a substantial number of shares, or the perception that such issuances or resales may occur, could adversely affect the market price of our common stock and make it more difficult for us to sell equity securities in the future at prices that we consider acceptable. The purchase price for shares sold under the AMPA is based on a discount to market prices determined over specified measurement periods. Accordingly, if the market price of our common stock declines, we may be required to issue a greater number of shares to raise the same amount of proceeds, resulting in greater dilution to existing stockholders. Sales under the AMPA may also place downward pressure on the market price of our common stock, which could further increase the number of shares required to be issued in subsequent sales. Our ability to issue shares under the AMPA remains subject to Nasdaq stockholder-approval requirements, applicable exchange-cap and beneficial-ownership limitations, the continued effectiveness and availability of the resale registration statement and other contractual conditions. Subsequent to September 30, 2026, we sold an additional 219,593 shares of common stock under the ATM Program. We may issue additional shares under the ATM Program, equity compensation plans, acquisition agreements or other financing and strategic arrangements. These issuances may substantially dilute the ownership and voting interests of our existing stockholders. The outstanding warrants issued in the registered direct offering may be exercised only at the election of their holders. We will not receive additional proceeds unless those warrants are exercised for cash, and they may expire without being exercised. If the warrants are exercised, the issuance of the underlying shares will result in additional dilution. The actual dilution resulting from these arrangements will depend on the number of shares issued, the applicable issuance prices, the market price of our common stock and the extent to which outstanding warrants are exercised. Significant dilution or a substantial increase in the number of shares available for public resale could adversely affect the market price and trading liquidity of our common stock.

  • Share Price & Shareholder Rights - Risk 5
    We are an "emerging growth company" and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors.

    We are an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we do not intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including: - not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act;- not being required to comply with any requirements that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the consolidated financial statements;- reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and - exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the trading prices for our securities may be more volatile. We may take advantage of these exemptions until the last day of our fiscal year following the fifth anniversary of the completion of our initial public offering. However, if any of the following events occur prior to the end of such five-year period, (i) our annual gross revenue exceeds $1.235 billion, (ii) we issue more than $1.0 billion of non-convertible debt in any three-year period or (iii) we become a "large accelerated filer," (as defined in Rule 12b-2 under the Exchange Act), we will cease to be an emerging growth company prior to the end of such five-year period. We will be deemed to be a "large accelerated filer" at such time that we (a) have an aggregate worldwide market value of common equity securities held by non-affiliates of $700 million or more as of the last business day of our most recently completed fiscal year, (b) have been required to file annual and quarterly reports under the Exchange Act, for a period of at least twelve months and (c) have filed at least one annual report pursuant to the Exchange Act. Even after we no longer qualify as an emerging growth company, we may still qualify as a "smaller reporting company," which would allow us to take advantage of many of the same exemptions from disclosure requirements including reduced disclosure obligations regarding executive compensation in this Report and our other periodic reports and proxy statements. Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations.

  • Share Price & Shareholder Rights - Risk 6
    Our Amended and Restated Certificate of Incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America are the exclusive forums for substantially all disputes between us and our stockholders, including claims under the Securities Act of 1933, as amended (the "Securities Act") and the Exchange Act, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

    Our Amended and Restated Certificate of Incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for: - any derivative action or proceeding brought on our behalf;- any action asserting a breach of fiduciary duty;- any action asserting a claim against us or any of our directors, officers, employees or agents arising under the DGCL, our Amended and Restated Certificate of Incorporation or our Amended and Restated Bylaws;- any action or proceeding to interpret, apply, enforce or determine the validity of our Amended and Restated Certificate of Incorporation or our Amended and Restated Bylaws; and - any action asserting a claim against us or any of our directors, officers, employees or agents that is governed by the internal-affairs doctrine. Our Amended and Restated Certificate of Incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act and the Exchange Act. These exclusive-forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our Amended and Restated Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions. We note that there is uncertainty as to whether a court would enforce such exclusive-forum provision and that provision may result in increased costs for investors to bring a claim.

  • Share Price & Shareholder Rights - Risk 7
    Provisions in our corporate charter documents and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

    Provisions in our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: - establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;- require that stockholder actions must be affected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;- limit who may call stockholder meetings; and - require the approval of the holders of at least 66.66% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws or remove a director. Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law ("DGCL"), which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired more than 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.

  • Share Price & Shareholder Rights - Risk 8
    Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions and matters submitted to stockholders for approval.

    Our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates, in the aggregate, beneficially own approximately 22.14% of our outstanding common stock, based on the number of shares of our common stock outstanding as of March 23, 2026. As a result, these persons, acting together, would be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation or sale of all or substantially all of our assets or other significant corporate transactions. In addition, these persons, acting together, may have the ability to control the management and affairs of our company. Accordingly, this concentration of ownership may harm the market price of our common stock by: - delaying, deferring or preventing a change in control;- entrenching our management and/or the board of directors;- impeding a merger, consolidation, takeover or other business combination involving us; or - discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. In addition, some of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the price at which shares were sold in our public offering and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders.

  • Share Price & Shareholder Rights - Risk 9
    If equity research analysts do not publish research or reports, or publish unfavorable research or reports about us, our business or our market, our stock price and trading volume could decline.

    The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. We do not currently have and may never obtain research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts, or the content and opinions included in their reports. The price of our shares could decline if one or more equity research analysts downgrade our shares or issue other unfavorable commentary or research about us. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our shares could decrease, which in turn could cause the trading price or trading volume of our common stock to decline.

  • Share Price & Shareholder Rights - Risk 10
    If we are not able to comply with the applicable continued listing requirements or standards of The Nasdaq Stock Market LLC, Nasdaq could delist our common stock, which could limit investors' ability to make transactions in our securities and subject us to additional trading restrictions.

    Our shares of our common stock are listed on the Capital Market tier of the Nasdaq Stock Market, or Nasdaq, under the symbol "NXL." Nasdaq has rules for continued listing, including, without limitation, minimum market capitalization, minimum stockholders' equity and other requirements. In order to maintain that listing, we must satisfy minimum financial and other continued listing requirements and standards, including the Minimum Bid Price Rule (as discussed below) and those regarding director independence and independent committee requirements, minimum stockholders' equity, and certain corporate governance requirements. There can be no assurances that we will be able to comply with the applicable listing standards. On January 21, 2026, the Company received a deficiency letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based upon the closing bid price of the Company's common stock, par value $0.001 per share, for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Requirement"). The Notice has no immediate effect on the continued listing status of the Common Stock on The Nasdaq Capital Market, and, therefore, the Company's listing remains fully effective. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided a compliance period of 180 calendar days from the date of the Notice, or until July 20, 2026, to regain compliance with the Minimum Bid Requirement. To regain compliance, the closing bid price of the Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days prior to July 20, 2026. If the Company is not in compliance with the Minimum Bid Requirement by July 20, 2026, the Company may be afforded a second 180 calendar day compliance period. To qualify for this additional compliance period, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price requirement. If Nasdaq delists our common stock from trading on its exchange and we are not able to list our common stock on another national securities exchange, we expect our common stock could be quoted on an over-the-counter market. If this were to occur, we could face significant adverse consequences, including: - a limited availability of market quotations for our common stock;- reduced liquidity for our common stock;- a determination that our common stock is a "penny stock," which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;- a limited amount of news and analyst coverage; and - a decreased ability to obtain additional financing in the future.

  • Share Price & Shareholder Rights - Risk 11
    The trading price of our common stock has been and is likely to be volatile and to fluctuate substantially, which could result in substantial losses for purchasers of our common stock.

    Our stock price has been, and is likely to be, volatile. The stock market in general and the market for companies in our industry in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. Volatility in our common stock is also subject to risks and uncertainties, including those discussed in this "Risk Factors" section. These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling their shares of our common stock and may otherwise negatively affect the liquidity of our common stock. As a result of this volatility, investors may not be able to sell their shares at or above the price paid. Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming and could divert our management's attention and our resources. Furthermore, during litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common stock.

  • Share Price & Shareholder Rights - Risk 12
    Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or products.

    Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through equity offerings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or products or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to a third party to develop and market products that we would otherwise prefer to develop and market ourselves.

See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.

FAQ

What are “Risk Factors”?
Risk factors are any situations or occurrences that could make investing in a company risky. The Securities and Exchange Commission (SEC) requires that publicly traded companies disclose their most significant risk factors. This is so that potential investors can consider any risks before they make an investment. They also offer companies protection, as a company can use risk factors as liability protection. This could happen if a company underperforms and investors take legal action as a result. It is worth noting that smaller companies, that is those with a public float of under $75 million on the last business day, do not have to include risk factors in their 10-K and 10-Q forms, although some may choose to do so.
How do companies disclose their risk factors?
Publicly traded companies initially disclose their risk factors to the SEC through their S-1 filings as part of the IPO process. Additionally, companies must provide a complete list of risk factors in their Annual Reports (Form 10-K) or (Form 20-F) for “foreign private issuers”. Quarterly Reports also include a section on risk factors (Form 10-Q) where companies are only required to update any changes since the previous report. According to the SEC, risk factors should be reported concisely, logically and in “plain English” so investors can understand them.
How can I use TipRanks risk factors in my stock research?
Use the Risk Factors tab to get data about the risk factors of any company in which you are considering investing. You can easily see the most significant risks a company is facing. Additionally, you can find out which risk factors a company has added, removed or adjusted since its previous disclosure. You can also see how a company’s risk factors compare to others in its sector. Without reading company reports or participating in conference calls, you would most likely not have access to this sort of information, which is usually not included in press releases or other public announcements. A simplified analysis of risk factors is unique to TipRanks.
What are all the risk factor categories?
TipRanks has identified 6 major categories of risk factors and a number of subcategories for each. You can see how these categories are broken down in the list below. 1. Financial & Corporate Accounting & Financial Operations - risks related to accounting loss, value of intangible assets, financial statements, value of intangible assets, financial reporting, estimates, guidance, company profitability, dividends, fluctuating results. Share Price & Shareholder Rights – risks related to things that impact share prices and the rights of shareholders, including analyst ratings, major shareholder activity, trade volatility, liquidity of shares, anti-takeover provisions, international listing, dual listing. Debt & Financing – risks related to debt, funding, financing and interest rates, financial investments. Corporate Activity and Growth – risks related to restructuring, M&As, joint ventures, execution of corporate strategy, strategic alliances. 2. Legal & Regulatory Litigation and Legal Liabilities – risks related to litigation/ lawsuits against the company. Regulation – risks related to compliance, GDPR, and new legislation. Environmental / Social – risks related to environmental regulation and to data privacy. Taxation & Government Incentives – risks related to taxation and changes in government incentives. 3. Production Costs – risks related to costs of production including commodity prices, future contracts, inventory. Supply Chain – risks related to the company’s suppliers. Manufacturing – risks related to the company’s manufacturing process including product quality and product recalls. Human Capital – risks related to recruitment, training and retention of key employees, employee relationships & unions labor disputes, pension, and post retirement benefits, medical, health and welfare benefits, employee misconduct, employee litigation. 4. Technology & Innovation Innovation / R&D – risks related to innovation and new product development. Technology – risks related to the company’s reliance on technology. Cyber Security – risks related to securing the company’s digital assets and from cyber attacks. Trade Secrets & Patents – risks related to the company’s ability to protect its intellectual property and to infringement claims against the company as well as piracy and unlicensed copying. 5. Ability to Sell Demand – risks related to the demand of the company’s goods and services including seasonality, reliance on key customers. Competition – risks related to the company’s competition including substitutes. Sales & Marketing – risks related to sales, marketing, and distribution channels, pricing, and market penetration. Brand & Reputation – risks related to the company’s brand and reputation. 6. Macro & Political Economy & Political Environment – risks related to changes in economic and political conditions. Natural and Human Disruptions – risks related to catastrophes, floods, storms, terror, earthquakes, coronavirus pandemic/COVID-19. International Operations – risks related to the global nature of the company. Capital Markets – risks related to exchange rates and trade, cryptocurrency.